{
    "clinical_study": {
        "@rank": "10042", 
        "arm_group": [
            {
                "arm_group_label": "ALKS 5461-A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALKS 5461-B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALKS 5461 Dose 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALKS 5461 Dose 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALKS 5461 Dose 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to test the safety of ALKS 5461 in healthy adults."
        }, 
        "brief_title": "A Study of ALKS 5461 in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Pharmacokinetics", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be in good physical health\n\n          -  Body mass index of 18-30 kg/m2\n\n          -  Agree to use an approved method of birth control for the duration of the study\n\n          -  Additional criteria may apply\n\n        Exclusion Criteria:\n\n          -  Currently pregnant or breastfeeding\n\n          -  History of or current infection with Hepatitis B Virus, Hepatitis C Virus or Human\n             Immunodeficiency Virus (HIV)\n\n          -  Current or history of any clinically significant medical or psychiatric condition\n\n          -  Current abuse or dependence on alcohol or any illicit drugs\n\n          -  Have used nicotine within 90 days\n\n          -  Have used St. John's Wort or consumed grapefruit, grapefruit juice, or juices\n             containing grapefruit within 30 days\n\n          -  Have used any prescription or over-the-counter medication, including natural health\n             products (with the exception of prescription birth control or hormonal replacements,\n             acetaminophen, ibuprofen, or multivitamins) within 14 days\n\n          -  Have used opioids 30 days prior to screening or have an anticipated need for opioid\n             medication at any point during the study\n\n          -  Have a history of intolerance or hypersensitivity to buprenorphine or opioid\n             antagonists (eg, naltrexone, naloxone)\n\n          -  Additional criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068105", 
            "org_study_id": "ALK5461-209"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ALKS 5461-A", 
                    "ALKS 5461-B", 
                    "ALKS 5461 Dose 1", 
                    "ALKS 5461 Dose 2", 
                    "ALKS 5461 Dose 3"
                ], 
                "description": "Sublingual tablet", 
                "intervention_name": "ALKS 5461", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Sublingual tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ALKS 5461", 
            "samidorphan"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66212"
                }, 
                "name": "Alkermes Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1, Randomized, Two-part Study to Evaluate the Relative Bioavailability of Two Formulations of ALKS 5461 and the Effect of Dose Titration of ALKS 5461 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Alkermes", 
            "last_name": "Randall Marshall, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The parameters for determining the bioavailability include Cmax, AUC last, and AUC(0-infinity).", 
            "measure": "Relative bioavailability of ALKS 5461 treatment groups", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety and tolerability:  Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "source": "Alkermes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alkermes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}